Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Children 4 to 8 years of age~* Complete medical records documenting receiving a previous hepatitis B vaccination during the first year of life (for Cohort A and B only)~* Complete 3-dose vaccination with either a primary series of RECOMBIVAX HB or a primary series of ENGERIX-B (for Cohort A and B only)~Exclusion Criteria:~* Birth mother known to be a carrier of hepatitis B virus (Cohort C only)~* History of previous hepatitis B vaccine~* History of vaccination with any hepatitis B vaccine (Cohort C only)~* Known of suspected hypersensitivity to any component of RECOMBIVAX HB or ENGERIX-B (eg aluminum, yeast) recent administration of hepatitis B immune globulin (HBIg), serum immune globulin, or any other blood-derived product~* Receipt of investigational drugs or vaccines within 3 months prior to study vaccine or planned within study period~* Impairment of immunologic function or recent use of immunomodulatory medications~* A Combination of different hepatitis B vaccines used in the primary vaccination series (Cohort A and B only)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- 5 µg Modified Process Hepatitis B Vaccine Booster (Group 1) (Type: ACTIVE_COMPARATOR): Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine (Booster Dose).
- 10 µg ENGERIX-B™ Booster (Group 2) (Type: ACTIVE_COMPARATOR): Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a dose of 10µg/per 0.5 ml ENGERIX-B™ (Booster Dose)
- 5 µg Modified Process Hepatitis B Vaccine Booster (Group 3) (Type: ACTIVE_COMPARATOR): Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine, (Booster Dose).
- 10 µg ENGERIX-B™ Booster (Group 4) (Type: ACTIVE_COMPARATOR): Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 10µg/0.5 ml dose of ENGERIX-B™ (Booster Dose).
- 5 µg Modified Process Hepatitis B Vaccine (Group 5) (Type: EXPERIMENTAL): Participants did not receive a prior vaccination with a hepatitis B vaccine.~During the study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete